You are here

Further Development of MT 100 Halted

August 8, 2005 -- POZEN Inc. (NASDAQ: POZN) announced that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous Systems Drugs Advisory Committee met yesterday to specifically address the risk of tardive dyskinesia, an involuntary neurological movement disorder associated with the use of metoclopramide hydrochloride, one of the components of MT 100. The Advisory Committee voted that the potential, but unquantified, risk for tardive dyskinesia would outweigh the benefits, as defined by the FDA, of metoclopramide hydrochloride in combination with naproxen sodium. The company received a "not approvable" letter from the FDA in May 2004.

"Based on a thoughtful review of the outcome of yesterday's meeting, we have decided to discontinue further development of MT 100 in the U.S.," said Dr. John R. Plachetka, POZEN's chairman, president and chief executive officer. "Part of the reason for this is that we expect to file the Trexima NDA shortly, and Trexima has already demonstrated greater efficacy without the metoclopramide risk associated with MT 100."

POZEN has licensed Trexima to GlaxoSmithKline for commercialization in the U.S. In addition to Trexima, POZEN's pipeline of product candidates include PN 100, PN 200, and PA 100, along with lornoxicam parenteral and oral opportunities.

Source: Pozen, Inc.

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
Rare Disorder Typically Co-occurs With Cancer